Sanofi completes the acquisition of Dynavax

赛诺菲完成对Dynavax的收购

Paris, February 10, 2026.

巴黎，2026年2月10日。

Sanofi today announced that it has completed the

赛诺菲今天宣布已完成

acquisition of Dynavax Technologies Corporation

收购Dynavax Technologies Corporation

(Dynavax). The acquisition includes Dynavax’s adult hepatitis B vaccine HEPLISAV-B, which is currently marketed in the US and is differentiated by its two-dose regimen over one month. It also includes Dynavax’s shingles vaccine candidate (Z-1018), which is currently in phase 1/2 studies, and additional vaccine pipeline projects..

（Dynavax）。此次收购包括Dynavax的成人乙型肝炎疫苗HEPLISAV-B，该疫苗目前在美国市场销售，并以其一个月内两剂的接种方案而与众不同。收购还包括Dynavax的带状疱疹疫苗候选药物（Z-1018），该药物目前处于1/2期研究阶段，以及其他疫苗管线项目。

This acquisition augments Sanofi’s presence in adult immunization by bringing together Dynavax’s vaccines with Sanofi’s commercial reach, global scale, and development capabilities.

此次收购通过将Dynavax的疫苗与赛诺菲的商业覆盖、全球规模和开发能力相结合，增强了赛诺菲在成人免疫领域的地位。

The tender offer for all outstanding shares of Dynavax common stock, par value $0.001 per share expired one minute after 11:59 P.M. EST, on February 9, 2026. The minimum condition and all the other conditions to the offer have been satisfied, and on February 10, 2026, Sanofi accepted for payment and will promptly pay for all shares validly tendered and not validly withdrawn..

Dynavax普通股的所有已发行股份（每股面值0.001美元）的要约收购于2026年2月9日美国东部时间晚上11点59分后一分钟到期。要约的最低条件及其他所有条件均已满足，2026年2月10日，赛诺菲接受了所有有效提交且未被有效撤回的股份，并将迅速支付这些股份的款项。

Following its acceptance of the tendered shares, Sanofi completed its acquisition of Dynavax through the merger of a wholly owned subsidiary of Sanofi with and into Dynavax, pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with Dynavax continuing as the surviving corporation and becoming an indirect, wholly owned subsidiary of Sanofi.

在接纳要约股份后，赛诺菲通过其全资子公司与Dynavax依据特拉华州普通公司法第251(h)条进行合并，完成了对Dynavax的收购，Dynavax继续作为存续公司，并成为赛诺菲的间接全资子公司。

In connection with the merger, all Dynavax shares not validly tendered in the tender offer have been converted into the right to receive the same $15.50 per share in cash, without interest, subject to any applicable withholding taxes, that would have been paid had such shares been validly tendered in the tender offer.

与合并相关，所有未在要约收购中有效投标的Dynavax股份已转换为获得每股15.50美元现金的权利，不计利息，且需扣除任何适用的预扣税，这与这些股份在要约收购中被有效投标时应得的金额相同。

As of February 10, 2026, Dynavax common stock will cease to be traded on the NASDAQ Global Select Stock Market..

截至2026年2月10日，Dynavax普通股将停止在纳斯达克全球精选股票市场交易。

About Sanofi

关于赛诺菲

Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more.

赛诺菲是一家以研发为驱动、以人工智能为助力的生物制药公司，致力于改善人们的生活并实现引人注目的增长。我们运用对免疫系统的深刻理解，开发药物和疫苗，为全球数百万人提供治疗和保护，同时拥有一个创新的研发管线，有望使数百万人进一步受益。

Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.

我们的团队以一个目标为指导：我们追求科学的奇迹以改善人们的生活；这激励我们通过应对当今最紧迫的医疗、环境和社会挑战，推动进步并为我们所服务的人民和社区带来积极影响。赛诺菲在巴黎泛欧交易所（EURONEXT: SAN）和纳斯达克（NASDAQ: SNY）上市。

Media Relations

媒体关系

Sandrine Guendoul

桑德琳·根杜尔

| +33 6 25 09 14 25 |

| +33 6 25 09 14 25 |

sandrine.guendoul@sanofi.com

桑德琳·根杜尔@赛诺菲.com

Evan Berland

埃文·贝兰德

| +1 215 432 0234 |

| +1 215 432 0234 |

evan.berland@sanofi.com

艾文·伯兰@赛诺菲.com

Léo Le Bourhis

里奥·勒布尔希斯

| +33 6 75 06 43 81 |

| +33 6 75 06 43 81 |

leo.lebourhis@sanofi.com

leo.lebourhis@sanofi.com

Victor Rouault

维克多·鲁奥

| +1 617 356 4751 |

| +1 617 356 4751 |

victor.rouault@sanofi.com

victor.rouault@sanofi.com

Timothy Gilbert

蒂莫西·吉尔伯特

| +1 516 521 2929 |

| +1 516 521 2929 |

timothy.gilbert@sanofi.com

timothy.gilbert@sanofi.com

Léa Ubaldi

蕾阿·乌巴尔迪

| +33 6 30 19 66 46 |

| +33 6 30 19 66 46 |

lea.ubaldi@sanofi.com

lea.ubaldi@sanofi.com

Ekaterina Pesheva

叶卡捷琳娜·佩舍娃

| +1 410 926 6780 |

| +1 410 926 6780 |

ekaterina.pesheva@sanofi.com

叶卡捷琳娜·佩舍娃@赛诺菲.com

Investor Relations

投资者关系

Thomas Kudsk Larsen

托马斯·库德斯克·拉森

| +44 7545 513 693 |

| +44 7545 513 693 |

thomas.larsen@sanofi.com

托马斯.拉森@赛诺菲.com

Alizé Kaisserian

阿利泽·凯塞里安

| +33 6 47 04 12 11 |

| +33 6 47 04 12 11 |

alize.kaisserian@sanofi.com

alize.kaisserian@sanofi.com

Keita Browne

凯塔·布朗

| +1 781 249 1766 |

| +1 781 249 1766 |

keita.browne@sanofi.com

keita.browne@sanofi.com

Nathalie Pham

娜塔莉·范

| +33 7 85 93 30 17 |

| +33 7 85 93 30 17 |

nathalie.pham@sanofi.com

娜塔莉·冯@赛诺菲.com

Nina Goworek

尼娜·戈沃雷克

| +1 908 569 7086 |

| +1 908 569 7086 |

nina.goworek@sanofi.com

尼娜·戈沃雷克@赛诺菲.com

Thibaud Châtelet

蒂博·沙泰莱

| +33 6 80 80 89 90 |

| +33 6 80 80 89 90 |

thibaud.chatelet@sanofi.com

thibaud.chatelet@sanofi.com

Yun Li

李云

| +33 6 84 00 90 72 |

| +33 6 84 00 90 72 |

yun.li3@sanofi.com

yun.li3@sanofi.com

Sanofi forward looking statement

赛诺菲前瞻性声明

Forward-looking statements are statements that are not historical facts. These statements may include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product, and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance.

前瞻性声明是指并非历史事实的声明。这些声明可能包括关于产品市场和其他潜力的预测和估计，或关于产品未来潜在收入及其基本假设的声明，关于未来财务结果、事件、运营、服务、产品开发和潜力的计划、目标、意图和期望的声明，以及关于未来表现的声明。

Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “will be”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward looking information and statements.

前瞻性声明通常可以通过“预期”、“预计”、“相信”、“将是”、“意图”、“估计”、“计划”等词语进行识别。尽管赛诺菲的管理层认为这些前瞻性声明中反映的预期是合理的，但投资者应注意，前瞻性信息和声明受到各种风险和不确定性的约束，其中许多难以预测且通常超出赛诺菲的控制范围，可能导致实际结果和发展与这些前瞻性信息和声明中表达或暗示或预测的内容存在重大差异。

These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful and other risks associated with executing business combination transactions, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the acquisition will not be realized, risks related to future opportunities and plans for the combi.

这些风险和不确定性包括但不限于：意外的监管行动或延迟，或可能影响产品可用性或商业潜力的政府监管，产品可能无法取得商业成功，以及与执行业务合并交易相关的其他风险，例如业务可能无法成功整合、整合可能比预期更困难、耗时或成本更高，或收购的预期收益无法实现，还涉及与组合未来机会和计划相关的风险。

Attachment

附件

Press Release

新闻发布

Share

分享